• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Italy·Healthcare·ARBS.MI
Share

ARTERRA BIOSCIENCE Stocks

€ 3.06Last Updated 30.07.2026

Issuer Rating

5/7
Performance

Strong

Risk

Considerable

Recommendation

Hold

Market Cap

€ 22.52M

€ 3.06
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Arterra Bioscience S.p.A. is a biotechnology company fundamentally driven by scientific research, concentrating on the discovery and development of a wide range of ingredients and nature-based solutions. The firm's activities encompass the creation of advanced technological frameworks, innovative extraction methodologies, and foundational raw materials, specifically tailored for the beauty, agricultural, and nutritional supplement sectors. Established in 2003, Arterra Bioscience S.p.A. is headquartered in Naples, Italy.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

31.07.2026 21:35

Three Fed officials said interest rates need to be raised to combat inflation

31.07.2026 20:36

Nvidia Finds Itself in the Unfamiliar Role of an Undervalued Growth Stock — Morningstar

31.07.2026 19:29

"There's no end in sight to the rise in capital expenditures": The four Big Tech companies' investments in AI have already exceeded $1 trillion

31.07.2026 18:43

Profits at the two leading U.S. oil companies have skyrocketed. They've found a "weak spot."

31.07.2026 18:37

Novo Nordisk shares plummeted 10% after a heart drug trial failed

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026